|
1
|
Sharma S, Kelly TK and Jones PA:
Epigenetics in cancer. Carcinogenesis. 31:27–36. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Dawson MA and Kouzarides T: Cancer
epigenetics: From mechanism to therapy. Cell. 150:12–27. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Greer EL and Shi Y: Histone methylation: A
dynamic mark in health, disease and inheritance. Nat Rev Genet.
13:343–357. 2012. View
Article : Google Scholar : PubMed/NCBI
|
|
4
|
Hoffmann I, Roatsch M, Schmitt ML, Carlino
L, Pippel M, Sippl W and Jung M: The role of histone demethylases
in cancer therapy. Mol Oncol. 6:683–703. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Li X, Su Y, Pan J, Zhou Z, Song B, Xiong E
and Chen Z: Connexin 26 is down-regulated by KDM5B in the
progression of bladder cancer. Int J Mol Sci. 14:7866–7879. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Sun H, Jiang W, Hu J and Ma Z: Prognostic
value of elevated KDM5B expression in patients with laryngeal
squamous cell carcinoma. Int J Clin Exp Pathol. 12:3500–3506.
2019.PubMed/NCBI
|
|
7
|
Bamodu OA, Huang WC, Lee WH, Wu A, Wang
LS, Hsiao M, Yeh CT and Chao TY: Aberrant KDM5B expression promotes
aggressive breast cancer through MALAT1 overexpression and
downregulation of hsa-miR-448. BMC Cancer. 16:1602016. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Plch J, Hrabeta J and Eckschlager T: KDM5
demethylases and their role in cancer cell chemoresistance. Int J
Cancer. 144:221–231. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Cloos PAC, Christensen J, Agger K and
Helin K: Erasing the methyl mark: Histone demethylases at the
center of cellular differentiation and disease. Genes Dev.
22:1115–1140. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Li G, Kanagasabai T, Lu W, Zou MR, Zhang
SM, Celada SI, Izban MG, Liu Q, Lu T, Ballard BR, et al: KDM5B is
essential for the hyperactivation of PI3K/AKT signaling in prostate
tumorigenesis. Cancer Res. 80:4633–4643. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Kuo YT, Liu YL, Adebayo BO, Shih PH, Lee
WH, Wang LS, Liao YF, Hsu WM, Yeh CT and Lin CM: JARID1B Expression
plays a critical role in chemoresistance and stem cell-like
phenotype of neuroblastoma cells. PLoS One. 10:e01253432015.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Maris JM: Recent advances in
neuroblastoma. N Engl J Med. 362:2202–2211. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Cheung NK and Dyer MA: Neuroblastoma:
Developmental biology, cancer genomics, and immunotherapy. Nat Rev
Cancer. 13:397–411. 2013. View
Article : Google Scholar : PubMed/NCBI
|
|
14
|
Nara K, Kusafuka T, Yoneda A, Oue T,
Sangkhathat S and Fukuzawa M: Silencing of MYCN by RNA interference
induces growth inhibition, apoptotic activity and cell
differentiation in a neuroblastoma cell line with MYCN
amplification. Int J Oncol. 30:1189–1196. 2007.PubMed/NCBI
|
|
15
|
M. S. MYCN Amplification in Neuroblastoma,
. Brodeur GM, Sawada T and Tsuchida YVP: Neuroblastoma. Elsevier
Science B.V; pp. 75–84. 2000
|
|
16
|
Kang JH, Rychahou PG, Ishola TA, Qiao J,
Evers BM and Chung DH: MYCN silencing induces differentiation and
apoptosis in human neuroblastoma cells. Biochem Biophys Res Commun.
351:192–197. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Maeshima R, Moulding D, Stoker AW and Hart
SL: MYCN Silencing by RNAi induces neurogenesis and suppresses
proliferation in models of neuroblastoma with resistance to
retinoic acid. Nucleic Acid Ther. 30:237–248. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Bachetti T, Di Paolo D, Di Lascio S,
Mirisola V, Brignole C, Bellotti M, Caffa I, Ferraris C, Fiore M,
Fornasari D, et al: PHOX2B-mediated regulation of ALK expression:
In vitro identification of a functional relationship between two
genes involved in neuroblastoma. PLoS One. 5:e131082010. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Di Paolo D, Pastorino F, Brignole C,
Corrias MV, Emionite L, Cilli M, Tamma R, Priddy L, Amaro A,
Ferrari D, et al: Combined replenishment of miR-34a and let-7b by
targeted nanoparticles inhibits tumor growth in neuroblastoma
preclinical models. Small. 16:e19064262020. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Olechnowicz SW, Fedele AO and Peet DJ:
Hypoxic Induction of the Regulator of G-protein signalling 4 gene
is mediated by the hypoxia-inducible factor pathway. PLoS One.
7:e445642012. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Zaatiti H, Abdallah J, Nasr Z, Khazen G,
Sandler A and Abou-Antoun TJ: Tumorigenic proteins upregulated in
the MYCN-amplified IMR-32 human neuroblastoma cells promote
proliferation and migration. Int J Oncol. 52:787–803.
2018.PubMed/NCBI
|
|
22
|
Cormier N, Yeo A, Fiorentino E and Paxson
J: Optimization of the wound scratch assay to detect changes in
murine mesenchymal stromal cell migration after damage by soluble
cigarette smoke extract. J Vis Exp. e534142015.PubMed/NCBI
|
|
23
|
Pfaffl MW, Horgan GW and Dempfle L:
Relative expression software tool (REST) for group-wise comparison
and statistical analysis of relative expression results in
real-time PCR. Nucleic Acids Res. 30:e362002. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Bedrnicek J, Vicha A, Jarosova M,
Holzerova M, Cinatl J Jr, Michaelis M, Cinatl J and Eckschlager T:
Characterization of drug-resistant neuroblastoma cell lines by
comparative genomic hybridization. Neoplasma. 52:415–419.
2005.PubMed/NCBI
|
|
25
|
Procházka P, Libra A, Zemanová Z,
Hřebačková J, Poljaková J, Hraběta J, Bunček M, Stiborová M and
Eckschlager T: Mechanisms of ellipticine-mediated resistance in
UKF-NB-4 neuroblastoma cells. Cancer Sci. 103:334–341. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Kanwal R and Gupta S: Epigenetic
modifications in cancer. Clin Genet. 81:303–311. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Pippa S, Mannironi C, Licursi V, Bombardi
L, Colotti G, Cundari E, Mollica A, Coluccia A, Naccarato V, La
Regina G, et al: Small molecule inhibitors of KDM5 histone
demethylases increase the radiosensitivity of breast cancer cells
overexpressing JARID1B. Molecules. 24:17392019. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Xu W, Zhou B, Zhao X, Zhu L, Xu J, Jiang
Z, Chen D, Wei Q, Han M, Feng L, et al: KDM5B demethylates H3K4 to
recruit XRCC1 and promote chemoresistance. Int J Biol Sci.
14:1122–1132. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Xiang Y, Zhu Z, Han G, Ye X, Xu B, Peng Z,
Ma Y, Yu Y, Lin H, Chen AP and Chen CD: JARID1B is a histone H3
lysine 4 demethylase up-regulated in prostate cancer. Proc Natl
Acad Sci USA. 104:19226–19231. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Klein BJ, Piao L, Xi Y, Rincon-Arano H,
Rothbart SB, Peng D, Wen H, Larson C, Zhang X, Zheng X, et al: The
histone-H3K4-specific demethylase KDM5B Binds to its substrate and
product through distinct PHD fingers. Cell Rep. 6:325–335. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Lu PJ, Sundquist K, Baeckstrom D, Poulsom
R, Hanby A, Meier-Ewert S, Jones T, Mitchell M, Pitha-Rowe P,
Freemont P and Taylor-Papadimitriou J: A novel gene (PLU-1)
containing highly conserved putative DNA/chromatin binding motifs
is specifically up-regulated in breast cancer. J Biol Chem.
274:15633–15645. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Yamane K, Tateishi K, Klose RJ, Fang J,
Fabrizio LA, Erdjument-Bromage H, Taylor-Papadimitriou J, Tempst P
and Zhang Y: PLU-1 Is an H3K4 demethylase involved in
transcriptional repression and breast cancer cell proliferation.
Mol Cell. 25:801–812. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Hayami S, Yoshimatsu M, Veerakumarasivam
A, Unoki M, Iwai Y, Tsunoda T, Field HI, Kelly JD, Neal DE, Yamaue
H, et al: Overexpression of the JmjC histone demethylase KDM5B in
human carcinogenesis: Involvement in the proliferation of cancer
cells through the E2F/RB pathway. Mol Cancer. 9:592010. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Yamamoto S, Wu Z, Russnes HG, Takagi S,
Peluffo G, Vaske C, Zhao X, Moen Vollan HK, Maruyama R, Ekram MB,
et al: JARID1B is a luminal lineage-driving oncogene in breast
cancer. Cancer Cell. 25:762–777. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Wang L, Mao Y, Du G, He C and Han S:
Overexpression of JARID1B is associated with poor prognosis and
chemotherapy resistance in epithelial ovarian cancer. Tumour Biol.
36:2465–2472. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Roesch A, Becker B, Meyer S, Wild P,
Hafner C, Landthaler M and Vogt T: Retinoblastoma-binding protein
2-homolog 1: A retinoblastoma-binding protein downregulated in
malignant melanomas. Mod Pathol. 18:1249–1257. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Roesch A, Fukunaga-Kalabis M, Schmidt EC,
Zabierowski SE, Brafford PA, Vultur A, Basu D, Gimotty P, Vogt T
and Herlyn M: A Temporarily distinct subpopulation of slow-cycling
melanoma cells is required for continuous tumor growth. Cell.
141:583–594. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Smith V and Foster J: High-risk
neuroblastoma treatment review. Children (Basel).
5:1142018.PubMed/NCBI
|
|
39
|
Feriancikova B, Feglarova T, Krskova L,
Eckschlager T, Vicha A and Hrabeta J: Miat is an upstream regulator
of NMYC and the disruption of the MIAT/NMYC axis induces cell death
in NMYC amplified neuroblastoma cell lines. Int J Mol Sci.
22:33932021. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Zhang L, Sokolowski N, Atmadibrata B and
Tao L: Histone demethylase JARID1B promotes cell proliferation but
is downregulated by N-Myc oncoprotein. Oncol Rep. 31:1935–1939.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Zhang J, An X, Han Y, Ma R, Yang K, Zhang
L, Chi J, Li W, Llobet-Navas D, Xu Y and Jiang Y: Overexpression of
JARID1B promotes differentiation via SHIP1/AKT signaling in human
hypopharyngeal squamous cell carcinoma. Cell Death Dis.
7:e23582016. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
YQ H, Y Z, RJ Z and XD M: Down-regulation
of JARID1B expression inhibits cell proliferation, induces
apoptosis and blocks cell cycle in human acute lymphoblastic
leukemia cells. Eur Rev Med Pharmacol Sci. 22:1366–1373.
2018.PubMed/NCBI
|
|
43
|
Shigekawa Y, Hayami S, Ueno M, Miyamoto A,
Suzaki N, Kawai M, Hirono S, Okada KI, Hamamoto R and Yamaue H:
Overexpression of KDM5B/JARID1B is associated with poor prognosis
in hepatocellular carcinoma. Oncotarget. 9:34320–34335. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Yang Z, Xu JX, Fang DP and Ke J: Analysis
of key genes reveal lysine demethylase 5B promotes prostate cancer
progression. Oncol Lett. 20:622020.PubMed/NCBI
|
